These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26744530)

  • 21. Nonspecific Inhibition of IL6 Family Cytokine Signalling by Soluble gp130.
    Widjaja AA; Cook SA
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung.
    Maeda Y; Tsuchiya T; Hao H; Tompkins DH; Xu Y; Mucenski ML; Du L; Keiser AR; Fukazawa T; Naomoto Y; Nagayasu T; Whitsett JA
    J Clin Invest; 2012 Dec; 122(12):4388-400. PubMed ID: 23143308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.
    Drosten M; Barbacid M
    J Mol Med (Berl); 2016 Feb; 94(2):121-35. PubMed ID: 26526121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.
    Wang Y; Hou N; Cheng X; Zhang J; Tan X; Zhang C; Tang Y; Teng Y; Yang X
    Int J Biol Sci; 2017; 13(5):652-659. PubMed ID: 28539837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3.
    Greenhill CJ; Rose-John S; Lissilaa R; Ferlin W; Ernst M; Hertzog PJ; Mansell A; Jenkins BJ
    J Immunol; 2011 Jan; 186(2):1199-208. PubMed ID: 21148800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer.
    Edmonds MD; Boyd KL; Moyo T; Mitra R; Duszynski R; Arrate MP; Chen X; Zhao Z; Blackwell TS; Andl T; Eischen CM
    J Clin Invest; 2016 Jan; 126(1):349-64. PubMed ID: 26657862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
    Akbay EA; Koyama S; Liu Y; Dries R; Bufe LE; Silkes M; Alam MM; Magee DM; Jones R; Jinushi M; Kulkarni M; Carretero J; Wang X; Warner-Hatten T; Cavanaugh JD; Osa A; Kumanogoh A; Freeman GJ; Awad MM; Christiani DC; Bueno R; Hammerman PS; Dranoff G; Wong KK
    J Thorac Oncol; 2017 Aug; 12(8):1268-1279. PubMed ID: 28483607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pivotal Role of the Chromatin Protein Nupr1 in Kras-Induced Senescence and Transformation.
    Grasso D; Bintz J; Lomberk G; Molejon MI; Loncle C; Garcia MN; Lopez MB; Urrutia R; Iovanna JL
    Sci Rep; 2015 Nov; 5():17549. PubMed ID: 26617245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression.
    Tsukamoto H; Fujieda K; Hirayama M; Ikeda T; Yuno A; Matsumura K; Fukuma D; Araki K; Mizuta H; Nakayama H; Senju S; Nishimura Y
    Cancer Res; 2017 May; 77(9):2279-2291. PubMed ID: 28235765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice.
    Ye H; Zhang C; Wang BJ; Tan XH; Zhang WP; Teng Y; Yang X
    Oncogene; 2014 Oct; 33(43):5133-8. PubMed ID: 24213574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.
    Liu S; Gandler HI; Tošić I; Ye DQ; Giaccone ZT; Frank DA
    Mol Cancer Res; 2021 Aug; 19(8):1283-1295. PubMed ID: 33931487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma.
    Ali SA; Justilien V; Jamieson L; Murray NR; Fields AP
    Cancer Cell; 2016 Mar; 29(3):367-378. PubMed ID: 26977885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis.
    Shin J; Lee JC; Baek KH
    Cancer Lett; 2014 Jan; 342(1):70-81. PubMed ID: 24051307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.
    Cicchini M; Buza EL; Sagal KM; Gudiel AA; Durham AC; Feldser DM
    Cell Rep; 2017 Feb; 18(8):1958-1969. PubMed ID: 28228261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.
    Weng TY; Yen MC; Huang CT; Hung JJ; Chen YL; Chen WC; Wang CY; Chang JY; Lai MD
    Gene Ther; 2014 Oct; 21(10):888-96. PubMed ID: 25077772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer.
    Alhayyani S; McLeod L; West AC; Balic JJ; Hodges C; Yu L; Smith JA; Prodanovic Z; Bozinovski S; Kumar B; Ruwanpura SM; Saad MI; Jenkins BJ
    Oncogene; 2022 Feb; 41(6):809-823. PubMed ID: 34857889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis.
    D'Amico S; Shi J; Martin BL; Crawford HC; Petrenko O; Reich NC
    Genes Dev; 2018 Sep; 32(17-18):1175-1187. PubMed ID: 30135074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS
    Baltanás FC; García-Navas R; Rodríguez-Ramos P; Calzada N; Cuesta C; Borrajo J; Fuentes-Mateos R; Olarte-San Juan A; Vidaña N; Castellano E; Santos E
    Nat Commun; 2023 Sep; 14(1):5856. PubMed ID: 37730692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer.
    Tien JC; Chugh S; Goodrum AE; Cheng Y; Mannan R; Zhang Y; Wang L; Dommeti VL; Wang X; Xu A; Hon J; Kenum C; Su F; Wang R; Cao X; Shankar S; Chinnaiyan AM
    Proc Natl Acad Sci U S A; 2021 May; 118(20):. PubMed ID: 33972443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.